slide1
Download
Skip this Video
Download Presentation
Protein Delivery Sciences

Loading in 2 Seconds...

play fullscreen
1 / 18

Protein Delivery Sciences - PowerPoint PPT Presentation


  • 151 Views
  • Uploaded on

Protein Delivery Sciences. Overview of PDS Biotechnology. Versamune TM nanotechnology Curative and protective, immunotherapeutic nano -particle technology Applicable to unmet clinical needs in infectious diseases and cancer Lead product – HPV infection and cancer Product 2 - Melanoma

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Protein Delivery Sciences' - denzel


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide2

Overview of PDS Biotechnology

  • VersamuneTM nanotechnology
    • Curative and protective, immunotherapeutic nano-particle technology
  • Applicable to unmet clinical needs in infectious diseases and cancer
    • Lead product – HPV infection and cancer
    • Product 2 - Melanoma
  • Experienced management team
slide3

Management Team

  • Frank Bedu-Addo, Ph.D. – President and CEO
    • KBI BioPharma, Cardinal Health, Schering-Plough, Elan
    • Overseen operations/P&L: Pharma & emerging biotech
  • Gregory Conn, Ph.D. – Chief Scientific Officer
    • 35 years expertise, Merck, Regeneron, Covance Biotech
    • 8 Drug patents
  • Leaf Huang, Ph.D.(Distinguished Chair, Pharmaceutics, UNC Chapel Hill - Scientific founder, R&D Support)
slide4

Advisory Teams

  • Board of Directors
    • De Lyle Bloomquist (CEO, General Chemical Products)
    • Cameron Durrant, M.D. (Global VP, Infectious Dis., Strategic Marketing, Johnson & Johnson)
    • Ron Labrum (CEO, Fenwal, Inc.)
    • Kent Payne, Ph.D. (VP, GM Cardinal Health Pharmaceutical Development, now Catalent Pharma)
  • Scientific Board (External Members)
    • Darron Brown, M.D. (Professor, Infectious Diseases, IU)
    • Mark Einstein, M.D. (Director, OBGYN, Montefiore Med. Ctr.)
    • Michel Klein, M.D. (CEO Canvac)
    • Lisa Rohan, Ph.D. (Assist. Prof. Pharmaceutics, Univ. of Pitt)
slide5

Single Dose VersamuneTM-HPV Therapy Induces Complete Tumor Regression in Pre-clinical Studies

Cancer Immunology Immunotherapy 57, 2008

slide11

The VersamuneTM Solution

  • Highly Potent Cures and Prevention
    • Demonstrated in HPV-related cancer
    • Demonstrated in Melanoma (NIH funded )
  • Simple and cost effective
    • Nanoparticles + disease-associated protein
  • Safe and Unique Mechanism of Action
    • Activates MAP Kinase
    • NIH funded toxicology: Safety at > 40X therapeutic dose
slide12

VersamuneTM - Intellectual Property

  • The technology involving the use of cationic lipids in immunotherapies was acquired by PDS Biotechnology in June 2006
  • Patent # 7303881, issue date 12/04/2007
  • 3 Additional composition and application patents filed in 2008-2009
slide13

Business Strategy and Revenue Generation

  • Phase 1 human clinical trials (2010)
    • FDA IND submission Q1 2010
  • Revenue generation
    • Strategic technology out-licensing (2010/2011)
    • Commercialize and market PDS proprietary products (2015/2016)
slide14

Partnerships

  • Merck AG – 2009
    • Exclusive IP and Supply Agreement
  • National Cancer Institute’s Nanotech Lab (NCL) – 2008
    • PDS selected as affiliate
    • NCL funded collaboration towards clinical trials
  • Leading US Academic Institution - 2007
    • Sponsored research agreement
    • PDS maintains IP
slide15

Selected Highlights

  • VersamuneTM-HPV IND Studies
    • In-vivo toxicology: Safe >40X active dose (NIH-funded)
    • In-vitro immunology and toxicology: Safe profile (By NCL)
    • High efficacy in human model systems (NIH-funded)
    • Robust manufacturing process and product stability
slide16

Funding

  • $4M raised 2006-2008
  • $8-10M Series A in 2009
    • $5.5 M - VersamuneTM-HPV
      • GMP manufacturing
      • Phase I clinical trials
    • $3.0M – Indications 2 & 3
      • VersamuneTM-Melanoma
      • VersamuneTM-Hepatitis or Herpes
        • Complete IND (2011/2012)
slide17

In Summary

  • A unique platform with solid patent position for immunotherapeutic products
  • Simple, safe, cost effective and potent immunotherapy treatments for cancer and infectious diseases
  • Superior efficacy in head-to-head with top technologies
  • Strong management team with stellar track record in management and drug development
  • Raising $10M in Series A
slide18

Thank You

Frank Bedu-Addo, Ph.D. - President and CEO

[email protected]

Tel: 513-807-6840

www.pdsbiotech.com

ad